How can IND strategy for psilocybin trials align with EMA-FDA advice?
A patient with treatment-resistant depression taught us that IND strategy for psilocybin trials must be patient-centered and aligned with both EMA and FDA expectations — here’s a story-driven roadmap with timeline tips and real examples.
Robert Maxwell
Oct 08, 2025
Breast cancer approvals
Psilocybin IND guidance
GLP-1 obesity regulation
Stroke endpoint alignment
